The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in Japan.


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 01 03 2019
pubmed: 27 6 2019
medline: 16 1 2020
entrez: 27 6 2019
Statut: ppublish

Résumé

A myriad of studies have demonstrated the clinical association of systemic inflammatory and nutrition status (SINS) including C-reactive protein/albumin ratio (CAR), the neutrophil/lymphocyte ratio (NLR), and the platelet/hemoglobin ratio (PHR). This study aimed to investigate the predictive value of the score integrating these variables (CANLPH) in patients with renal cell carcinoma (RCC). Using cohort data from a multi-institutional study, 757 of 1109 patients were retrospectively analyzed. The optimal cutoff value for outcome prediction of continuous variables in CAR, NLR, and PHR was determined and the CANLPH score was then calculated as the sum score of 0 or 1 by the cutoff value in each ratio. The median follow-up time was 76 months for the patients who survived (n = 585) and 31 months for those who died (n = 172). The Youden Index offered an optimal cutoff of 1.5 for CAR and 2.8 for NLR, and a higher value from the cutoff was assigned as a score of 1. The cutoff value of the PHR was defined as 2.1 for males and 2.3 for females. The patients were assigned a CANLPH score of 0 (47.2%), 1 (31.3%), 2 (13.1%), or 3 (8.5%). In the multivariate analysis, the CANLPH score served as an independent predictor of cancer-specific mortality in both localized and metastatic RCC. The score was well-correlated with clinical outcome for the RCC patients. Because this score can be concisely measured at the point of diagnosis, physicians may be encouraged to incorporate this model into the treatment for RCC.

Sections du résumé

BACKGROUND BACKGROUND
A myriad of studies have demonstrated the clinical association of systemic inflammatory and nutrition status (SINS) including C-reactive protein/albumin ratio (CAR), the neutrophil/lymphocyte ratio (NLR), and the platelet/hemoglobin ratio (PHR). This study aimed to investigate the predictive value of the score integrating these variables (CANLPH) in patients with renal cell carcinoma (RCC).
METHODS METHODS
Using cohort data from a multi-institutional study, 757 of 1109 patients were retrospectively analyzed. The optimal cutoff value for outcome prediction of continuous variables in CAR, NLR, and PHR was determined and the CANLPH score was then calculated as the sum score of 0 or 1 by the cutoff value in each ratio.
RESULTS RESULTS
The median follow-up time was 76 months for the patients who survived (n = 585) and 31 months for those who died (n = 172). The Youden Index offered an optimal cutoff of 1.5 for CAR and 2.8 for NLR, and a higher value from the cutoff was assigned as a score of 1. The cutoff value of the PHR was defined as 2.1 for males and 2.3 for females. The patients were assigned a CANLPH score of 0 (47.2%), 1 (31.3%), 2 (13.1%), or 3 (8.5%). In the multivariate analysis, the CANLPH score served as an independent predictor of cancer-specific mortality in both localized and metastatic RCC.
CONCLUSION CONCLUSIONS
The score was well-correlated with clinical outcome for the RCC patients. Because this score can be concisely measured at the point of diagnosis, physicians may be encouraged to incorporate this model into the treatment for RCC.

Identifiants

pubmed: 31240592
doi: 10.1245/s10434-019-07530-5
pii: 10.1245/s10434-019-07530-5
doi:

Substances chimiques

Albumins 0
Biomarkers, Tumor 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2994-3004

Subventions

Organisme : Japan Society for the Promotion of Science: JSPS
ID : 17K16821

Auteurs

Kazumasa Komura (K)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan. uro051@osaka-med.ac.jp.
Translational Research Program, Osaka Medical College, Takatsuki City, Osaka, Japan. uro051@osaka-med.ac.jp.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. uro051@osaka-med.ac.jp.

Takeshi Hashimoto (T)

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Takuya Tsujino (T)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Ryu Muraoka (R)

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Takeshi Tsutsumi (T)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Naoya Satake (N)

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Tomohisa Matsunaga (T)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.

Yuki Yoshikawa (Y)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Tomoaki Takai (T)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Koichiro Minami (K)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Kohei Taniguchi (K)

Translational Research Program, Osaka Medical College, Takatsuki City, Osaka, Japan.

Hirofumi Uehara (H)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Tomohito Tanaka (T)

Translational Research Program, Osaka Medical College, Takatsuki City, Osaka, Japan.

Hajime Hirano (H)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Hayahito Nomi (H)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Naokazu Ibuki (N)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Kiyoshi Takahara (K)

Department of Urology, Fujita-Health University School of Medicine, Nagoya, Aichi, Japan.

Teruo Inamoto (T)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Yoshio Ohno (Y)

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Haruhito Azuma (H)

Department of Urology, Osaka Medical College, Takatsuki City, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH